SaMD Registration in SFDA (Software as a Medical Device)By Yumna Siraj|2024-12-13T18:59:13+03:0007/12/2024|Medical Devices|
MDMA Update and Change of InformationBy Mohamed Bashim|2024-12-13T18:59:25+03:0006/12/2024|Medical Devices|
Overview of SFDA Conditional Approval for New MedicinesBy Madiha Baaj|2024-12-07T21:01:53+03:0002/12/2024|Pharmaceuticals, Regulatory Affairs|
SFDA Drug Pricing Rules in Saudi ArabiaBy Rawd Alsubaie|2024-12-07T21:01:36+03:0030/11/2024|Pharmaceuticals, Regulatory Affairs|
Understanding RMP & RMMs in SFDA PV RegulationBy Yara Aljadeed|2024-11-23T00:49:21+03:0009/06/2024|Pharmacovigilance|
Scientific Office Requirements by SFDABy Regulatory Editor|2024-11-01T04:35:35+03:0001/03/2024|Regulatory Affairs|
Reporting Medical Device Incidents & Adverse Events to SFDABy Heba Rasheed|2024-11-01T04:16:55+03:0023/02/2024|Medical Devices, Regulatory Affairs|
Breakthrough Medicines Designation in SFDABy Madiha Baaj|2024-11-01T04:11:32+03:0012/02/2024|Pharmaceuticals, Regulatory Affairs|
How to implement PMCF in Saudi ArabiaBy Heba Rasheed|2024-11-01T03:57:38+03:0009/02/2024|Medical Devices, Regulatory Affairs|
Understanding Orphan Drug Designation (ODD) in SFDABy Madiha Baaj|2024-11-01T03:48:06+03:0009/02/2024|Pharmaceuticals|
